ONCTERNAL THERAPEUTICS, INC.

Analyst Reco. Oncternal Therapeutics, Inc.

Equities

ONCT

US68236P2065

Market Closed - Nasdaq Other stock markets 21:30:01 26/04/2024 BST			5-day change	1st Jan Change
8.29 ^USD	+0.48%		-6.43%	-22.70%

04-18	Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	CI
04-15	HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating	04-15	MT
Brookline Capital Upgrades Oncternal Therapeutics to Buy From Hold, Price Target is $2	12-04	MT
HC Wainwright Upgrades Oncternal Therapeutics to Buy From Neutral, Price Target is $2	18/09/23	MT
Maxim Downgrades Oncternal Therapeutics to Hold From Buy	04/04/23	MT
Oppenheimer Downgrades Oncternal Therapeutics to Perform From Outperform, Removes $9 Price Target	04/04/23	MT
Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy	04/04/23	MT
Cantor Fitzgerald Adjusts Price Target on Oncternal Therapeutics to $1.30 From $4, Keeps Overweight Rating	04/04/23	MT
HC Wainwright Downgrades Oncternal Therapeutics to Neutral From Buy	04/04/23	MT
Oppenheimer Adjusts Oncternal Therapeutics Price Target to $9 From $14, Maintains Outperform Rating	22/03/23	MT
Cantor Fitzgerald Initiates Oncternal Therapeutics With Overweight Rating, $4 Price Target	22/12/22	MT
Maxim Initiates Oncternal Therapeutics at Buy, Sets Price Target at $3.50	10/05/22	MT
BTIG Starts Oncternal Therapeutics at Buy With $5 Price Target	24/02/22	MT
ONCTERNAL THERAPEUTICS : Oppenheimer Adjusts Oncternal Therapeutics PT to $16 From $14, Maintains Outperform Rating	16/04/21	MT
ONCTERNAL THERAPEUTICS : Oppenheimer Starts Oncternal Therapeutics at Outperform with $14 Price Target	07/04/21	MT
ONCTERNAL THERAPEUTICS : Brookline Capital Initiates Coverage on Oncternal Therapeutics With Buy Rating, $16 Price Target	30/03/21	MT
ONCTERNAL THERAPEUTICS : Northland Starts Oncternal Therapeutics at Outperform With $21 Price Target	23/02/21	MT
Oncternal Therapeutics, Inc. Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma	11/03/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer